Elanco Animal Health (ELAN)
11.69
-0.01 (-0.09%)
At close: Jan 14, 2025, 3:59 PM
11.67
-0.13%
After-hours Jan 14, 2025, 07:56 PM EST
undefined% (undefined)
| Bid | 10.39 |
| Market Cap | 5.78B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.41 |
| PE Ratio (ttm) | 28.5 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.5 |
| Volume | 3,003,781 |
| Avg. Volume (20D) | 4,608,239 |
| Open | 11.72 |
| Previous Close | 11.70 |
| Day's Range | 11.47 - 11.87 |
| 52-Week Range | 11.11 - 18.80 |
| Beta | undefined |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indicati...
Sector Healthcare
IPO Date Sep 20, 2018
Employees 9,300
Stock Exchange NYSE
Ticker Symbol ELAN
Website https://www.elanco.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 36.93% from the latest price.
Buy 42.86%
Hold 42.86%
Sell 14.29%
Next Earnings Release
Elanco Animal Health is scheduled to release its earnings on Feb 24, 2025,
before market opens.
Analysts project revenue of $1.01B, reflecting a -2.42% YoY shrinking and earnings per share of 0.15, making a 87.50% increase YoY.
Analysts project revenue of $1.01B, reflecting a -2.42% YoY shrinking and earnings per share of 0.15, making a 87.50% increase YoY.
2 months ago ·
Source
+12.75%
Elanco Animal Health shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago ·
Source
-0.75%
Elanco shares are trading higher after the company received FDA approval for Credelio Quattro broad-spectrum canine oral parasiticide in a monthly dose.
